Figure 1
From: Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells
CTS treatment inhibits cell growth by suppressing STAT3 activity. (A) Chemical structure of CTS. (B,C) LN229 and U87-MG human GBM cells were treated with a series of concentrations of CTS for 24 or 48 h, and cell viability was determined with a CCK-8 assay. (D,E) Western blot analysis showing protein expression in LN229 and U87-MG cells using the indicated antibodies. (F,G) LN229 and U87-MG cells were treated with vehicle control or 4 μM CTS for different periods, and cell viability was determined with a CCK-8 assay. (H,I) LN229 and U87-MG cells were treated with vehicle control or 4 μM CTS for different periods, and protein expression was detected with the indicated antibodies (***P < 0.001, **P < 0.01, *P < 0.05).
